Compellis Pharmaceuticals Awarded Second Broad Patent From the U.S. Patent Office for Novel Obesity Therapy

BOSTON, MA--(Marketwire - October 27, 2008) - Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that they have been issued a second broad patent (7,138,107) by the U.S. Patent and Trademark Office (USPTO) for its invention entitled "Inhibition of olfactory neurosensory function to treat obesity and related disorders." The patent broadly protects key aspects of Compellis' novel obesity therapeutic strategy. Compellis has successfully demonstrated its therapeutic effect on weight gain in pre-clinical animal models and the results are published in "Pharmacology, Biochemistry and Behavior."